Related Experiment Video
Updated: May 4, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.2K
[New oral anticoagulants: who really needs them?]
1Klinik für Innere Medizin und Geriatrie, Evangelisches Krankenhaus Bielefeld (EvKB), Schildescher Str. 99, 33611, Bielefeld, Deutschland, heiner.berthold@evkb.de.
Der Internist
|January 9, 2014
Summary
New oral anticoagulants (NOAC) offer stroke prevention for atrial fibrillation but may reduce adherence due to dosing and lack of monitoring. Vitamin K antagonists (VKA) might better manage adherence issues.
Area of Science:
- Pharmacology
- Cardiology
- Internal Medicine
Context:
- Nonvalvular atrial fibrillation (NVAF) necessitates stroke prevention.
- New oral anticoagulants (NOAC) are alternatives to vitamin K antagonists (VKA).
- Randomized trials show NOAC superiority over warfarin in reducing clinical endpoints, albeit with small effect sizes.
Purpose:
- To evaluate the adherence and effectiveness of NOAC compared to VKA in stroke prevention for NVAF patients.
- To analyze factors influencing anticoagulation therapy effectiveness, including drug adherence and monitoring.
Summary:
- NOAC effectiveness is comparable to VKA, but superiority is diminished in centers with optimal anticoagulation management.
- Adherence is critical for anticoagulation efficacy; NOAC may pose adherence challenges due to twice-daily dosing and lack of routine monitoring.
- Vitamin K antagonists (VKA) may offer advantages in compensating for suboptimal adherence due to their longer half-lives.
Impact:
- Understanding adherence factors is crucial for optimizing stroke prevention strategies in NVAF.
- This research informs clinical practice regarding the choice between NOAC and VKA, considering patient adherence and monitoring capabilities.
- Highlights the importance of patient adherence and monitoring in achieving effective anticoagulation therapy outcomes.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K